Acalabrutinib, a second-generation oral irreversible BTK inhibitor, approved by the FDA for both MCL and CLL, was the subject of a now-completed phase Ib trial for RRMM (NCT02211014). This evidence concerns the gene BTK and mantle cell lymphoma.